A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
response
Immune responses to WT1 peptides will be measured by intracellular interferon-γ production assay and MHC tetramer analyses, if available for patient's HLA-type.
12-14 weeks after the initial WT1 peptide vaccine
No
Guenther Koehne, MD, PhD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
12-288
NCT01827137
April 2013
April 2015
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |